About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Rc3h1+
wild type
MGI:3581653
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Rc3h1m1Btlr/Rc3h1+ C57BL/6J-Rc3h1m1Btlr MGI:5789727
ht2
Rc3h1san/Rc3h1+ involves: C57BL/6JSfdAnu MGI:5445374
cx3
Icostm1Flv/Icostm1Flv
Rc3h1san/Rc3h1+
involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu MGI:5445418
cx4
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+
involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu MGI:5445417


Genotype
MGI:5789727
ht1
Allelic
Composition
Rc3h1m1Btlr/Rc3h1+
Genetic
Background
C57BL/6J-Rc3h1m1Btlr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rc3h1m1Btlr mutation (0 available); any Rc3h1 mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body




Genotype
MGI:5445374
ht2
Allelic
Composition
Rc3h1san/Rc3h1+
Genetic
Background
involves: C57BL/6JSfdAnu
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rc3h1san mutation (7 available); any Rc3h1 mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 36% of heterozygotes show tumors at 4-5 months of age and by 8-15 months of age about 50% of heterozygotes develop T-cell lymphoma
• prevalence of tumors is 1.6 times higher in females (65%) than in males (41%), regardless of age
• affected lymph nodes exhibit effacement of the nodal architecture, prominent vasularization, atypical T cells, and large B cells, features of angioimmunoblastic T-cell lymphoma, however they do not show expanded FDC networks
• clonal rearrangements in the TCR-beta genes are present in tumors

hematopoietic system
• 36% of heterozygotes show tumors at 4-5 months of age and by 8-15 months of age about 50% of heterozygotes develop T-cell lymphoma
• prevalence of tumors is 1.6 times higher in females (65%) than in males (41%), regardless of age
• affected lymph nodes exhibit effacement of the nodal architecture, prominent vasularization, atypical T cells, and large B cells, features of angioimmunoblastic T-cell lymphoma, however they do not show expanded FDC networks
• clonal rearrangements in the TCR-beta genes are present in tumors
• slight but significant increase in spleen weight; no difference in spleen size is seen between heterozygotes with or without tumors, indicating that splenomegaly does not correlate with lymphadenopathy
• non-tumor lymph nodes exhibit an increased frequency of follicular helper T cells compared to wild-type mice
• heterozygotes, both with and without tumors, develop hypergammaglobulinemia, showing a 2- to 3-fold increase in serum IgG levels
• heterozygotes with tumors have a 1.5-fold increase in total serum IgG levels compared to heterozygotes without tumors
• follicular T cells exhibit increased clonality compared with non-follicular T cells from the same lymph node, even in nontumor lymph nodes

immune system
• 36% of heterozygotes show tumors at 4-5 months of age and by 8-15 months of age about 50% of heterozygotes develop T-cell lymphoma
• prevalence of tumors is 1.6 times higher in females (65%) than in males (41%), regardless of age
• affected lymph nodes exhibit effacement of the nodal architecture, prominent vasularization, atypical T cells, and large B cells, features of angioimmunoblastic T-cell lymphoma, however they do not show expanded FDC networks
• clonal rearrangements in the TCR-beta genes are present in tumors
• slight but significant increase in spleen weight; no difference in spleen size is seen between heterozygotes with or without tumors, indicating that splenomegaly does not correlate with lymphadenopathy
• non-tumor lymph nodes exhibit an increased frequency of follicular helper T cells compared to wild-type mice
• heterozygotes, both with and without tumors, develop hypergammaglobulinemia, showing a 2- to 3-fold increase in serum IgG levels
• heterozygotes with tumors have a 1.5-fold increase in total serum IgG levels compared to heterozygotes without tumors
• follicular T cells exhibit increased clonality compared with non-follicular T cells from the same lymph node, even in nontumor lymph nodes
• tumor lymph nodes exhibit an increase in the number of macrophages within the paracortex with occasional foci of myeloid metaplasia, dense aggregates of small PAX5+ lymphocytes all over the parenchyma forming follicles without germinal centers, reactive B-blasts and small clusters of mature plasma cells in the interfollicular areas, polymorphic infiltrate composed of small- to medium-sized proliferating CD3+ lymphocytes in the interfollicular compartment, T cells that occasionally form rosettes around large blasts, sinusoidal dilatation, vessels filled with T cells, an increase in the proportion of B cells, an increase in the frequency of myeloid and dendritic cells with monocyte-derived dendritic cells showing a 2- to 3-fold expansion, a decrease in CD8+ dendritic cells, and an increase in proliferation of follicular helper T cells
• nonenlarged lymph nodes from tumor-bearing heterozygotes exhibit preserved nodal architecture, having both primary and secondary follicles with reactive germinal centers as well as an increase of mature plasma cells in the interfollicular area
• germinal centers are hyperplastic in nontumor lymph nodes of heterozygotes with tumors
• 53% of heterozygotes develop 1 to 4 enlarged lymph nodes, whereas other lymph nodes remain normal
• while some lymph nodes are larger due to tumor development, nontumor lymph nodes in heterozygotes are also often larger than control lymph nodes

growth/size/body
• slight but significant increase in spleen weight; no difference in spleen size is seen between heterozygotes with or without tumors, indicating that splenomegaly does not correlate with lymphadenopathy

endocrine/exocrine glands
• 36% of heterozygotes show tumors at 4-5 months of age and by 8-15 months of age about 50% of heterozygotes develop T-cell lymphoma
• prevalence of tumors is 1.6 times higher in females (65%) than in males (41%), regardless of age
• affected lymph nodes exhibit effacement of the nodal architecture, prominent vasularization, atypical T cells, and large B cells, features of angioimmunoblastic T-cell lymphoma, however they do not show expanded FDC networks
• clonal rearrangements in the TCR-beta genes are present in tumors

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
peripheral T-cell lymphoma DOID:0050749 J:189087




Genotype
MGI:5445418
cx3
Allelic
Composition
Icostm1Flv/Icostm1Flv
Rc3h1san/Rc3h1+
Genetic
Background
involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Icostm1Flv mutation (4 available); any Icos mutation (30 available)
Rc3h1san mutation (7 available); any Rc3h1 mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 5 of 25 double mutants develop T cell lymphoma
• tumor incidence (about 20%) is reduced compared to Rc3h1 heterozygotes (more than 50%)

endocrine/exocrine glands
• 5 of 25 double mutants develop T cell lymphoma

hematopoietic system
• 5 of 25 double mutants develop T cell lymphoma

immune system
• 5 of 25 double mutants develop T cell lymphoma




Genotype
MGI:5445417
cx4
Allelic
Composition
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+
Genetic
Background
involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd28tm1Mak mutation (13 available); any Cd28 mutation (37 available)
Rc3h1san mutation (7 available); any Rc3h1 mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 2 of 22 double mutants develop T cell lymphoma
• tumor incidence (about 10%) is reduced compared to Rc3h1 heterozygotes (more than 50%)

endocrine/exocrine glands
• 2 of 22 double mutants develop T cell lymphoma

hematopoietic system
• 2 of 22 double mutants develop T cell lymphoma

immune system
• 2 of 22 double mutants develop T cell lymphoma





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
01/06/2026
MGI 6.24
The Jackson Laboratory